Update on proposal to fund a pangenotypic hepatitis C treatment - glecaprevir and pibrentasvir (Maviret)

Update Medicines

This news item is more than two years old

The information on this page may no longer be accurate. If you have any questions, you can email us at media@pharmac.govt.nz

Update

PHARMAC would like to thank everyone who provided feedback on a proposal to fund glecaprevir and pibrentasvir (Maviret) for hepatitis C.

This was the subject of a consultation letter dated 20 July 2018, with a closing date for feedback of 13 August 2018.

After having reviewed the feedback, we have determined that we require additional time to consider the issues raised before a decision can be made on the proposal.

This means that a decision will not be made in time to implement the proposal from the earliest possible listing date of 1 October 2018 that was noted in the consultation. At this stage, we do not have a firm timeframe for when a decision will be made.

If you have any questions about this update, please contact Matthew Tyson, Therapeutic Group Manager, by email at hepc@pharmac.govt.nz.